• Consensus Rating: N/A
  • Consensus Price Target: €0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.05 (-0.07%)

This chart shows the closing price for MOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MorphoSys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MOR

Analyst Price Target is €0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for MorphoSys in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €10,000,000.00. The average price target represents a -100.00% upside from the last price of €67.60.

This chart shows the closing price for MOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in MorphoSys. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/16/2023JPMorgan Chase & Co.Set Target€11.00
3/10/2023JPMorgan Chase & Co.Set Target€11.00
3/2/2023JPMorgan Chase & Co.Set Target€11.00
1/9/2023JPMorgan Chase & Co.Set Target€11.00
1/6/2023Morgan StanleySet Target€12.50
1/3/2023JPMorgan Chase & Co.Set Target€11.00
1/3/2023The Goldman Sachs GroupSet Target€12.00
12/28/2022The Goldman Sachs GroupSet Target€12.00
12/22/2022The Goldman Sachs GroupSet Target€12.00
12/16/2022The Goldman Sachs GroupSet Target€12.00
11/25/2022Deutsche Bank AktiengesellschaftSet Target€13.00
11/21/2022JPMorgan Chase & Co.Set Target€18.00
11/14/2022JPMorgan Chase & Co.Set Target€32.50
10/31/2022JPMorgan Chase & Co.Set Target€32.50
10/24/2022Deutsche Bank AktiengesellschaftSet Target€18.00
10/24/2022JPMorgan Chase & Co.Set Target€32.50
10/17/2022JPMorgan Chase & Co.Set Target€32.50
9/28/2022JPMorgan Chase & Co.Set Target€32.50
8/10/2022JPMorgan Chase & Co.Set Target€32.50
8/4/2022The Goldman Sachs GroupSet Target€24.00
8/4/2022JPMorgan Chase & Co.Set Target€34.00
8/4/2022Berenberg BankSet Target€65.00
7/27/2022Deutsche Bank AktiengesellschaftSet Target€30.00
7/26/2022JPMorgan Chase & Co.Set Target€34.00
7/26/2022Berenberg BankSet Target€65.00
6/15/2022JPMorgan Chase & Co.Set Target€34.00
6/10/2022The Goldman Sachs GroupSet Target€24.00
5/27/2022Berenberg BankSet Target€65.00
5/17/2022JPMorgan Chase & Co.Set Target€34.00
5/11/2022JPMorgan Chase & Co.Set Target€34.00
5/5/2022Berenberg BankSet Target€65.00
5/4/2022Deutsche Bank AktiengesellschaftSet Target€30.00
3/24/2022Berenberg BankSet Target€65.00
3/22/2022Deutsche Bank AktiengesellschaftSet Target€30.00
3/17/2022JPMorgan Chase & Co.Set Target€40.00
3/17/2022BarclaysSet Target€36.00
3/11/2022Deutsche Bank AktiengesellschaftSet Target€46.00
2/1/2022Berenberg BankSet Target€124.00
1/31/2022BarclaysSet Target€36.00
1/17/2022JPMorgan Chase & Co.Set Target€40.00
1/10/2022Deutsche Bank AktiengesellschaftSet Target€46.00
1/10/2022BarclaysSet Target€47.00
1/10/2022JPMorgan Chase & Co.Set Target€40.00
1/5/2022Berenberg BankSet Target€124.00
1/4/2022JPMorgan Chase & Co.Lower Target€54.00 ➝ €40.00
11/15/2021Deutsche Bank AktiengesellschaftSet Target€46.00
11/12/2021Morgan StanleySet Target€76.00
11/11/2021Berenberg BankSet Target€124.00
11/11/2021BarclaysSet Target€47.00
11/11/2021The Goldman Sachs GroupSet Target€42.00
11/11/2021JPMorgan Chase & Co.Set Target€54.00
11/3/2021BarclaysSet Target€47.00
11/1/2021JPMorgan Chase & Co.Set Target€54.00
10/29/2021The Goldman Sachs GroupSet Target€42.00
10/21/2021Berenberg BankSet Target€124.00
10/6/2021JPMorgan Chase & Co.Set Target€54.00
9/27/2021Deutsche Bank AktiengesellschaftSet Target€46.00
9/17/2021Morgan StanleySet Target€75.00
9/13/2021The Goldman Sachs GroupSet Target€42.00
9/2/2021BarclaysSet Target€47.00
8/6/2021Deutsche Bank AktiengesellschaftSet Target€46.00
8/4/2021JPMorgan Chase & Co.Set Target€54.00
7/29/2021Berenberg BankSet Target€124.00
7/29/2021JPMorgan Chase & Co.Set Target€80.00
7/19/2021BarclaysSet Target€90.00
7/9/2021Morgan StanleySet Target€86.00
7/5/2021Stifel NicolausSet Target€97.00
6/16/2021Berenberg BankSet TargetBuy€140.00
6/14/2021JPMorgan Chase & Co.Set TargetNeutral€80.00
6/8/2021JPMorgan Chase & Co.Set TargetBuy€105.00
6/3/2021BarclaysSet TargetNeutral€90.00
6/3/2021Deutsche Bank AktiengesellschaftSet TargetBuy€116.00
6/2/2021JPMorgan Chase & Co.Set TargetBuy€105.00
5/24/2021Morgan StanleySet TargetBuy€90.00
5/21/2021JPMorgan Chase & Co.Set TargetBuy€105.00
5/11/2021The Goldman Sachs GroupSet TargetNeutral€75.00
5/11/2021Deutsche Bank AktiengesellschaftSet TargetBuy€116.00
5/6/2021Berenberg BankSet TargetBuy€140.00
5/6/2021Morgan StanleySet TargetNeutral€91.00
5/5/2021The Goldman Sachs GroupSet TargetNeutral€88.00
5/5/2021Deutsche Bank AktiengesellschaftSet TargetBuy€116.00
5/4/2021JPMorgan Chase & Co.Set TargetBuy€110.00
4/19/2021BarclaysSet TargetNeutral€90.00
4/8/2021Deutsche Bank AktiengesellschaftSet TargetBuy€116.00
3/25/2021JPMorgan Chase & Co.Set TargetBuy€110.00
3/22/2021The Goldman Sachs GroupSet TargetNeutral€88.00
3/17/2021Independent ResearchSet TargetBuy€95.00
3/17/2021Berenberg BankSet TargetBuy€140.00
3/16/2021Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
3/16/2021JPMorgan Chase & Co.Set TargetBuy€130.00
3/16/2021The Goldman Sachs GroupSet TargetNeutral€110.00
3/16/2021Royal Bank of CanadaSet TargetNeutral€130.00
3/3/2021Independent ResearchSet TargetBuy€120.00
3/3/2021Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
3/2/2021The Goldman Sachs GroupSet TargetNeutral€110.00
3/2/2021BarclaysSet TargetNeutral€90.00
2/10/2021BarclaysSet TargetNeutral€90.00
2/10/2021Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
2/9/2021The Goldman Sachs GroupSet TargetNeutral€110.00
2/9/2021JPMorgan Chase & Co.Set TargetBuy€130.00
1/22/2021BarclaysSet TargetNeutral€90.00
1/18/2021JPMorgan Chase & Co.Set TargetBuy€130.00
1/8/2021Morgan StanleySet TargetNeutral€105.00
1/4/2021JPMorgan Chase & Co.Set TargetBuy€130.00
12/14/2020Berenberg BankSet TargetBuy€140.00
12/3/2020JPMorgan Chase & Co.Set TargetBuy€120.00
11/27/2020Independent ResearchSet TargetBuy€120.00
11/25/2020Morgan StanleySet TargetNeutral€105.00
11/18/2020The Goldman Sachs GroupSet TargetNeutral€110.00
11/13/2020Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
11/13/2020Berenberg BankSet TargetBuy€140.00
11/13/2020BarclaysSet TargetNeutral€90.00
11/12/2020Royal Bank of CanadaSet TargetNeutral€130.00
10/28/2020The Goldman Sachs GroupSet TargetNeutral€110.00
10/14/2020The Goldman Sachs GroupSet TargetNeutral€110.00
10/5/2020Berenberg BankSet TargetBuy€140.00
10/5/2020The Goldman Sachs GroupSet TargetNeutral€110.00
10/2/2020BarclaysSet TargetNeutral€110.00
9/30/2020JPMorgan Chase & Co.Set TargetBuy€130.00
9/29/2020The Goldman Sachs GroupSet TargetNeutral€110.00
9/23/2020The Goldman Sachs GroupSet TargetNeutral€110.00
8/25/2020Independent ResearchSet TargetNeutral€117.00
8/17/2020BarclaysSet TargetNeutral€105.00
8/17/2020The Goldman Sachs GroupSet TargetNeutral€110.00
8/10/2020Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
8/3/2020Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
8/3/2020The Goldman Sachs GroupSet TargetNeutral€114.00
8/3/2020Royal Bank of CanadaSet TargetNeutral€130.00
8/3/2020JPMorgan Chase & Co.Set TargetBuy€130.00
7/27/2020Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
7/17/2020The Goldman Sachs GroupSet TargetNeutral€114.00
6/10/2020The Goldman Sachs GroupSet TargetNeutral€114.00
6/2/2020The Goldman Sachs GroupSet TargetNeutral€114.00
5/22/2020JPMorgan Chase & Co.Set TargetBuy€130.00
5/21/2020Royal Bank of CanadaSet TargetBuy€113.00
5/14/2020JPMorgan Chase & Co.Set TargetBuy€150.00
5/14/2020Independent ResearchSet TargetBuy€138.00
5/13/2020BarclaysSet TargetNeutral€105.00
5/12/2020HSBCSet TargetNeutral€114.00
5/8/2020The Goldman Sachs GroupSet TargetNeutral€114.00
5/7/2020JPMorgan Chase & Co.Set TargetBuy€150.00
5/7/2020Royal Bank of CanadaSet TargetBuy€113.00
4/15/2020The Goldman Sachs GroupSet TargetNeutral€114.00
4/7/2020The Goldman Sachs GroupSet TargetNeutral€114.00
3/24/2020BarclaysSet TargetNeutral€110.00
3/23/2020Berenberg BankSet TargetBuy€150.00
3/23/2020Independent ResearchSet TargetBuy€119.00
3/19/2020Royal Bank of CanadaSet TargetBuy€130.00
3/19/2020JPMorgan Chase & Co.Reiterated RatingBuy
3/3/2020Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
2/5/2020Berenberg BankSet TargetBuy€150.00
2/3/2020BarclaysSet TargetNeutral€110.00
1/23/2020Berenberg BankSet TargetBuy€150.00
1/22/2020Independent ResearchSet TargetNeutral€130.00
1/22/2020The Goldman Sachs GroupReiterated RatingNeutral
1/20/2020JPMorgan Chase & Co.Set TargetBuy€150.00
1/15/2020Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
1/13/2020Berenberg BankSet TargetBuy€145.00
1/13/2020The Goldman Sachs GroupSet TargetNeutral€114.00
1/13/2020JPMorgan Chase & Co.Set TargetBuy€150.00
1/6/2020JPMorgan Chase & Co.Set TargetBuy€150.00
1/2/2020The Goldman Sachs GroupSet TargetNeutral€114.00
12/11/2019JPMorgan Chase & Co.Set TargetBuy€130.00
12/10/2019Royal Bank of CanadaSet TargetBuy€130.00
12/10/2019Berenberg BankSet TargetBuy€145.00
12/6/2019Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
12/4/2019Berenberg BankSet TargetBuy€145.00
11/19/2019The Goldman Sachs GroupSet TargetNeutral€114.00
11/19/2019Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
11/19/2019Berenberg BankSet TargetBuy€145.00
11/19/2019Royal Bank of CanadaSet TargetBuy€130.00
11/18/2019JPMorgan Chase & Co.Set TargetBuy€130.00
11/11/2019Berenberg BankSet TargetBuy€145.00
11/7/2019Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
11/7/2019Royal Bank of CanadaSet TargetBuy€130.00
11/1/2019Independent ResearchSet TargetNeutral€110.00
11/1/2019Deutsche Bank AktiengesellschaftSet TargetBuy€129.00
10/30/2019JPMorgan Chase & Co.Set TargetBuy€130.00
10/29/2019Berenberg BankSet TargetBuy€150.00
10/29/2019Royal Bank of CanadaSet TargetBuy€130.00
10/29/2019The Goldman Sachs GroupSet TargetNeutral€114.00
9/26/2019The Goldman Sachs GroupSet TargetNeutral€114.00
9/24/2019Independent ResearchSet TargetNeutral€117.00
9/11/2019JPMorgan Chase & Co.Set TargetBuy€130.00
9/9/2019Berenberg BankSet TargetBuy€150.00
8/16/2019HSBCSet TargetSell€81.00
8/13/2019Independent ResearchSet TargetNeutral€116.00
8/9/2019Royal Bank of CanadaSet TargetBuy€130.00
8/8/2019Deutsche Bank AktiengesellschaftSet TargetBuy€133.00
8/7/2019The Goldman Sachs GroupSet TargetNeutral€114.00
8/7/2019JPMorgan Chase & Co.Set TargetBuy€120.00
8/5/2019Berenberg BankSet TargetBuy€150.00
7/18/2019Deutsche Bank AktiengesellschaftSet TargetBuy€133.00
7/16/2019JPMorgan Chase & Co.Set TargetBuy€120.00
7/4/2019Independent ResearchSet TargetNeutral€96.00
6/26/2019Independent ResearchSet TargetNeutral€96.00
6/24/2019Royal Bank of CanadaSet TargetSell€65.00
6/24/2019JPMorgan Chase & Co.Set TargetBuy€120.00
6/24/2019The Goldman Sachs GroupSet TargetNeutral€114.00
(Data available from 6/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.


  • No negative mentions tracked during this time.


  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
MorphoSys logo
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
Read More

Today's Range

Now: €67.60
Low: €67.60
High: €68.00

50 Day Range

MA: €67.58
Low: €65.65
High: €69.35

52 Week Range

Now: €67.60
Low: €14.52
High: €69.75


113,354 shs

Average Volume

153,687 shs

Market Capitalization

$2.55 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of MorphoSys?

The following Wall Street sell-side analysts have issued reports on MorphoSys in the last year:
View the latest analyst ratings for MOR.

What is the current price target for MorphoSys?

0 Wall Street analysts have set twelve-month price targets for MorphoSys in the last year. has the lowest price target set, forecasting a price of €10,000,000.00 for MorphoSys in the next year.
View the latest price targets for MOR.

What is the current consensus analyst rating for MorphoSys?

MorphoSys currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MOR.

What other companies compete with MorphoSys?

How do I contact MorphoSys' investor relations team?

MorphoSys' physical mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company's listed phone number is +49-89-899270. The official website for MorphoSys is www.morphosys.de. Learn More about contacing MorphoSys investor relations.